Objective: To analyze whether the use of an intermittent (IAD) versus continuous (CAD) androgen deprivation therapy for the treatment of biochemical progression after primary treatments (radical prostatectomy and radiation therapy) in hormone sensitive non-metastatic prostate cancer can influence the development of non-metastatic castration resistant prostate cancer (CRPC-M0) .

Intermittent versus continuous androgen deprivation therapy for biochemical progression after primary therapy in hormone-sensitive nonmetastatic prostate cancer. Comparative analysis in terms of CRPC-M0 progression / Salciccia, Stefano; Frisenda, Marco; Tufano, Antonio; Pierro, Giovanni Di; Bevilacqua, Giulio; Rosati, Davide; Gobbi, Luca; Basile, Greta; Moriconi, Martina; Mariotti, Gianna; Forte, Flavio; Carbone, Antonio; Pastore, Antonio; Cattarino, Susanna; Sciarra, Alessandro; Gentilucci, Alessandro. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 22:2(2024), pp. 74-83. [10.1016/j.clgc.2023.08.008]

Intermittent versus continuous androgen deprivation therapy for biochemical progression after primary therapy in hormone-sensitive nonmetastatic prostate cancer. Comparative analysis in terms of CRPC-M0 progression

Salciccia, Stefano;Frisenda, Marco;Tufano, Antonio;Pierro, Giovanni Di;Bevilacqua, Giulio;Gobbi, Luca;Basile, Greta;Moriconi, Martina;Forte, Flavio;Pastore, Antonio;Cattarino, Susanna;Sciarra, Alessandro
;
Gentilucci, Alessandro
2024

Abstract

Objective: To analyze whether the use of an intermittent (IAD) versus continuous (CAD) androgen deprivation therapy for the treatment of biochemical progression after primary treatments (radical prostatectomy and radiation therapy) in hormone sensitive non-metastatic prostate cancer can influence the development of non-metastatic castration resistant prostate cancer (CRPC-M0) .
2024
prostate cancer; intermittent androgen ablation
01 Pubblicazione su rivista::01a Articolo in rivista
Intermittent versus continuous androgen deprivation therapy for biochemical progression after primary therapy in hormone-sensitive nonmetastatic prostate cancer. Comparative analysis in terms of CRPC-M0 progression / Salciccia, Stefano; Frisenda, Marco; Tufano, Antonio; Pierro, Giovanni Di; Bevilacqua, Giulio; Rosati, Davide; Gobbi, Luca; Basile, Greta; Moriconi, Martina; Mariotti, Gianna; Forte, Flavio; Carbone, Antonio; Pastore, Antonio; Cattarino, Susanna; Sciarra, Alessandro; Gentilucci, Alessandro. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 22:2(2024), pp. 74-83. [10.1016/j.clgc.2023.08.008]
File allegati a questo prodotto
File Dimensione Formato  
Salciccia_Intermittent_2024.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 660.29 kB
Formato Adobe PDF
660.29 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1688448
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact